Welcome to our dedicated page for Becton Dickinson & Co SEC filings (Ticker: BDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Injection devices, diagnostic platforms, and interventional tools place Becton, Dickinson and Company (BD) at the heart of patient care—but they also generate sprawling disclosures that can exceed 300 pages. Finding where BD details FDA observations, segment margins, or litigation reserves is a challenge for busy professionals.
Stock Titan solves that problem. Our AI reads every line the moment it hits EDGAR, giving you Becton Dickinson SEC filings explained simply. Curious about a BD quarterly earnings report 10-Q filing? Get an instant summary of Life Sciences revenue shifts. Need Becton Dickinson insider trading Form 4 transactions? Real-time alerts flag each executive move. For deeper dives, open any document and let the platform highlight:
- Becton Dickinson annual report 10-K simplified—R&D spending, product safety notes, global supply-chain risks.
- Becton Dickinson 8-K material events explained—device recalls, acquisitions, leadership changes.
- Becton Dickinson proxy statement executive compensation—how incentives align with BD Medical, Life Sciences, and Interventional performance.
Whether you’re benchmarking margins with our BD earnings report filing analysis or monitoring Becton Dickinson executive stock transactions Form 4, the platform keeps you ahead. Spend less time decoding footnotes and more time acting on insights—understanding Becton Dickinson SEC documents with AI means clarity on every risk factor, growth driver, and insider trade in one place.
Becton, Dickinson and Company filed an 8-K reporting a material event: the company entered into a Third Amended and Restated Credit Agreement dated September 16, 2025 among Becton, Dickinson and Company, other parties to the agreement, and Citibank, N.A. as administrative agent. The filing identifies the credit agreement as Exhibit 10.1 and includes Inline XBRL interactive data on the cover page. The report also reiterates the company’s registered securities, including its common stock (BDX) and several listed note series. The filing provides the existence and counterparty for the amended credit facility but does not disclose the agreement’s financial terms, covenants, maturity, or commitments within the provided text.
Claire Fraser, a director of Becton, Dickinson and Company (BDX), reported a sale of 917 shares of BDX common stock on 09/10/2025 at a reported price of $187.50 per share. After the sale, the reporting person beneficially owned 22,226 shares in a direct ownership form. The Form 4 was signed by Donna Kalazdy by power of attorney on 09/11/2025.
Becton, Dickinson and Co. (BDX) Form 144 shows a proposed sale of 917 common shares through Merrill Lynch on 09/10/2025, with an aggregate market value of $171,862.50. The filer acquired these shares as a stock bonus on 01/23/2025 from Claire Marie Fraser and paid by stock bonus on the same date. The filing also discloses a recent sale of 863 shares on 08/08/2025 for gross proceeds of $165,879.90. Outstanding shares are listed as 286,627,469, making these transactions a very small fraction of total shares outstanding.
Christopher DelOrefice, EVP & Chief Financial Officer of Becton, Dickinson and Company (BDX), reported a transaction on 09/01/2025. The Form 4 shows 278 shares of BDX common stock were disposed under transaction code "F" with a reported price of $0. The explanatory note states these shares were withheld to satisfy tax withholding obligations related to the vesting of previously granted restricted stock units. After this withholding, Mr. DelOrefice beneficially owns 21,221 shares directly. The filing was signed by Donna Kalazdy by power of attorney on 09/02/2025.
Becton, Dickinson and Company insider Richard Byrd, serving as EVP & President Interventional, reported a transaction dated 09/01/2025 involving 216 shares of BDX common stock that were disposed at a reported price of $0. The filing shows 6,736 shares owned following the transaction. The explanatory note states these 216 shares were withheld to satisfy withholding taxes related to the vesting of previously granted restricted stock units. The Form 4 was signed by a power of attorney on 09/02/2025.
Michael Feld, EVP & President, Life Sciences at Becton, Dickinson & Co. (BDX), reported the sale of 57 shares of common stock on 08/22/2025 at a price of $197.99 per share, leaving him with 8,360 shares beneficially owned. The filing notes the sale was made pursuant to a Rule 10b5-1 plan adopted on August 2, 2024, indicating a prearranged, compliant insider trading plan.
Becton, Dickinson and Co. (BDX) filed a Form 144 reporting a proposed sale of 57 common shares through Morgan Stanley Smith Barney LLC. The filing states the shares were acquired as restricted stock units (RSUs) from the issuer on 08/20/2025 and the proposed approximate sale date is 08/22/2025. The filing shows an aggregate market value of $11,207.91 for the 57 shares and reports 286,627,469 shares outstanding. No securities of the issuer were reported sold by the filer in the past three months.
Michael Feld, EVP & President, Life Sciences at Becton, Dickinson and Company (BDX), reported a non-derivative disposition of 773 shares of BDX common stock on 08/20/2025. The filing uses transaction code F, and the explanatory note states these shares were withheld to satisfy tax withholding upon vesting of previously granted restricted stock units, so the reported price is shown as $0. After the withholding, Mr. Feld beneficially owned 8,417 shares directly. The Form 4 was signed by Donna Kalazdy by power of attorney on 08/22/2025.
Becton, Dickinson and Co. is reported as having 16,178,519 shares beneficially owned by T. Rowe Price Investment Management, Inc., representing 5.6% of the outstanding common stock. The filing shows T. Rowe Price holds sole voting power over 15,106,743 shares and sole dispositive power over 16,178,519 shares, and classifies the filer as an investment adviser. The filing includes a written certification that the shares are held in the ordinary course of business and are not held to change or influence control of the company.
This Schedule 13G discloses a passive, greater-than-5%-ownership stake in BDX by a large institutional investment adviser, providing investors clarity on a significant passive holder and the exact voting and dispositive powers reported.
Becton, Dickinson and Company (BDX) has a class of debt securities, the 0.034% Notes due 2025, that the New York Stock Exchange has notified for removal from listing and registration by filing Form 25. The Exchange states it complied with rules governing delisting and the filing records that the issuer complied with the Exchange's requirements under 17 CFR 240.12d2-2(c) while the Exchange referenced compliance under 17 CFR 240.12d2-2(b).
FAQ
What is the current stock price of Becton Dickinson & Co (BDX)?
What is the market cap of Becton Dickinson & Co (BDX)?
